Ctrl K
Last 45 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.36 | — | — | — | — | — | — | 0.66 | 4.31 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 11.54 | 1125.21 | 10.29 | — | — | 9.82 | — | — | 145.56 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +11357.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 26.67 | 15.59 | 29.62 | 11.20 | 10.84 | 5.24 | 79.32 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | +146.0% | +197.4% | -62.7% | -66.0% | -34.0% | — | +243.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | 5.00 | 1.06 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 46.5% | -88.9% | -17.2% | 102.5% | 1098.5% | 70.8% | — | — | 50.0% | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -225.6% | — | — | +2097.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -4744.3% | -120111.1% | -11006.8% | 1116.4% | 18863.9% | -1046.2% | — | — | -13447.3% | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -11380.7% | — | — | +240.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -4416.2% | -225766.7% | -3494.3% | 1909.0% | 14482.2% | -1338.8% | — | — | 3345.2% | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -16764.0% | — | — | +332.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — | -829.5% | -50.7% | -152.4% | -99.6% | -62.6% | -46.5% | -54.1% | -154.5% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -1225.2% | -9.1% | -181.5% | +35.5% | +14.3% | +82.0% | — | -7.3% | |
| ROA | -263.4% | -84.5% | -22.2% | -125.2% | -64.9% | -97.2% | -257.0% | 75.8% | 15.0% | 83.7% | -283.2% | -41.4% | -33.9% | -42.0% | -11.4% | -40.9% | -42.7% | -33.0% | -26.9% | -28.5% | -48.1% |
| — | +13.0% | +91.4% | -265.1% | -532.7% | -216.1% | +9.3% | +283.1% | +144.3% | +299.3% | -2383.7% | -1.2% | +20.8% | -27.2% | +57.7% | -43.6% | +11.2% | -5.5% | +40.8% | +68.2% | -21.2% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -305.1% | -513.0% | -1908.7% | -632.0% | -297.8% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -2.5% | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 3.04 | 2.02 | 1.25 | 0.52 | 0.64 | 0.46 | 2.58 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | +377.6% | +340.2% | -51.4% | -42.8% | +15.5% | — | -17.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.38 | 0.81 | 0.54 | 0.35 | 0.38 | 0.67 | 0.72 | 0.32 | 0.64 | 1.07 | 1.07 | 0.44 | 0.66 | 0.86 | 1.22 | 4.09 | 1.39 | 2.04 | 2.12 | 3.88 | 3.19 |
| — | +20.6% | -25.1% | +7.7% | -41.1% | -37.5% | -32.9% | -26.8% | -2.8% | +24.4% | -12.3% | -89.2% | -52.5% | -57.7% | -42.5% | +5.3% | -56.2% | +25.3% | +36.2% | +326.8% | +182.1% | |
| Quick Ratio | 0.31 | 0.63 | -86005.09 | 0.28 | 0.31 | 0.54 | 0.57 | 0.26 | 0.64 | 1.07 | 1.07 | 0.44 | 0.66 | 0.86 | 1.22 | 4.09 | 1.39 | 2.04 | 2.12 | 3.88 | 3.19 |
| — | +17.3% | -15031461.4% | +7.3% | -52.4% | -49.7% | -46.5% | -41.3% | -2.8% | +24.4% | -12.3% | -89.2% | -52.5% | -57.7% | -42.5% | +5.3% | -56.2% | +25.3% | +36.2% | +326.8% | +182.1% | |
| Interest Coverage | -224.96 | — | — | — | -55.21 | -407.35 | -669.74 | — | — | — | -6.14 | — | — | -68234.32 | — | -6.41 | -38.77 | -47.69 | -45.20 | -40.14 | -48.80 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 45 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OTLK stock.
Outlook Therapeutics, Inc.'s current P/E is -0.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Outlook Therapeutics, Inc.'s current operating margin is -4744.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Outlook Therapeutics, Inc.'s business trajectory between earnings reports.